CCCC

$2.76

Post-MarketAs of Mar 17, 8:00 PM UTC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.76
Potential Upside
5%
Whystock Fair Value$2.90
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$269.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-44.44%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
7.60

Recent News

MarketBeat
Mar 14, 2026

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays’ 28th Annual Global Healthcare Conference, highlighting progress in multiple myeloma and an upcoming decision point for its EGFR program in non-small cell l

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 10, 2026

C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy rating on the stock. The price target increase reflects growing conviction following the initiation timing of […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 7, 2026

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program cemsidomide and a development strategy aimed at potential accelerated approval pathways. Focus on targete

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 6, 2026

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?

Here is how BrightSpring Health Services, Inc. (BTSG) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.